TABLE 4.
Comparison of the demographic characteristics and clinical outcomes of all the 232 patients who received at least 1 vaccine dose and developed COVID-19 across the subsequent doses and comparative analysis between the 135 fully vaccinated vs 341 nonvaccinated patients
| Parameters | All COVID-19+ | After first dose | <15 d after the second dose | Fully vaccinated | P a | Nonvaccinated | P b |
|---|---|---|---|---|---|---|---|
| (n = 232) | (n = 68) | (n = 29) | (n = 135) | (n = 341) | |||
| Median age (IQR), y | 53 (45–60) | 52 (47–59) | 56 (48–62) | 52 (44–60) | 0.381 | 50 (42–58) | 0.197 |
| Age category, n (%) | 0.742 | 0.374 | |||||
| 30–60 y | 173 (74) | 52 (76) | 20 (69) | 100 (74) | 268 (79) | ||
| Over 60 y | 61 (26) | 16 (24) | 9 (31) | 35 (26) | 73 (21) | ||
| Male gender, n (%) | 140 (60) | 46 (68) | 17 (59) | 77 (57) | 0.365 | 214 (63) | 0.249 |
| Diabetes, n (%) | 24 (10) | 9 (13) | 2 (7) | 14 (10) | 0.595 | 107 (31) | <0.0001 |
| Deceased donor transplant, n (%) | 157 (67) | 43 (63) | 22 (76) | 93 (68) | 0.104 | 203 (60) | 0.159 |
| Median length of transplant (IQR), y | 7 (3–12) | 7 (3–12) | 5 (1–13) | 7 (4–12) | 0.439 | 7 (3–12) | 0.095 |
| Maintenance immunosuppression, n (%) | 0.237 | 0.044 | |||||
| TAC-Pred-AZA | 68 (29) | 15 (22) | 14 (48) | 39 (29) | 97 (29) | ||
| TAC-Pred-MPA | 90 (38) | 27 (40) | 9 (32) | 53 (40) | 135 (40) | ||
| CSA-Pred-AZA | 38 (16) | 15 (22) | 2 (7) | 21 (15) | 28 (8) | ||
| TAC-Pred-mTORi | 23 (10) | 5 (7) | 3 (10) | 15 (11) | 32 (9) | ||
| Other | 15 (7) | 6 (9) | 1 (3) | 7 (5) | 44 (13) | ||
| Need for hospitalization due to COVID-19, n (%) | 146 (62) | 48 (71) | 18 (62) | 80 (59) | 0.286 | 168 (49) | 0.049 |
| Need for mechanical ventilation, n (%) | 84 (36) | 33 (49) | 11 (38) | 40 (30) | 0.030 | 95 (28) | 0.585 |
| 28-d mortality associated with COVID-19, n (%) | 69 (30) | 30 (44) | 10 (34) | 30 (22) | 0.003 | 85 (25) | 0.534 |
aRefers to comparison between the 3 groups of vaccinated patients who developed COVID-19.
bRefers to the comparison between fully vaccinated vs nonvaccinated patients who developed COVID-19.
AZA, azathioprine; CSA, cyclosporine; COVID-19, coronavirus disease 2019; IQR, interquartile range; MPA, mycophenolic acid; mTORi, mechanistic target of rapamycin inhibitor; Pred, prednisone; TAC, tacrolimus.